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Abstract 
We have isolated and sequenced a cDNA for human liver LTB, w-hydroxylase. The cDNA encoded a protein of 520 amino acids with a molecular 
weight of 59,853 Da. The cDNA-deduced amino acid sequence showed 87.3% homology to that of human polymorphonuclear leukocytes (PMN) 
LTB, w-hydroxylase (CYP4F3). Northern blot analysis revealed that the mRNA hybridized to the specific cDNA fragment is expressed in human 
liver, but not in human PMN. The microsomes from yeast cells transfected with the cDNA catalyzed the o-hydroxylation of LTB4 with a K,,, of 44.8 
pM. These results clearly show that a new form of the CYP4F LTB, w-hydroxylase xists in human liver. 
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1. Introduction 
Leukotriene (LT) B, is a potent chemotactic agent and 
plays a role as a mediator of inflammation [l]. Human 
polymorphonuclear leukocytes (PMN) not only generate 
LTB, from arachidonic acid by the 5lipoxygenase path- 
way, but also convert LTB, into biologically less active 
products by the w-oxidation pathway, the first step of 
which is catalyzed by LTB4 o-hydroxylase [2-61. Recent 
studies in our laboratories revealed that LTB, w-hydrox- 
ylase is a P-450 [7], which shows about 40% amino acid 
sequence homology to several o-hydroxylases toward 
fatty acids and prostaglandins belonging to the CYP4A 
subfamily [8]. This new P-450 was named CYP4F3 [7] 
according to the uniform nomenclature system of the 
P-450 superfamily [93. On the other hand, the liver is the 
principal organ for metabolic inactivation of LTB4 as 
well as cysteinyl leukotrienes. Rat liver microsomes or 
hepatocyte suspensions catalyze the w-hydroxylation of 
LTB, [l&l 31. Sumimoto et al. [ 1 l] provided evidence for 
the participation of a P-450 in the w-hydroxylation of 
LTB,. However, nothing is known about the enzyme 
system for the metabolism of LTB, in human liver. In the 
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Abbreviations: P-450, cytochrome P-450; LTB,, leukotriene B,; PMN, 
polymorphonuclear leukocytes; bp, base pair(s). CYP refers to a cyto- 
chrome P-450 gene(s) and cDNA(s), which is the nomenclature recom- 
mended by Nelson et al. [9]. 
The nucleotide sequence reported in this paper has been submitted to 
DDBJ, EMBL, and GenBank with accession umber D26480. 
present study, we have found the capability of human 
liver microsomes to w-hydroxylate LTB,. Furthermore, 
we have cloned human liver LTB, w-hydroxylase. This 
enzyme shows 87.3% amino acid sequence homology to 
the human PMN LTB, w-hydroxylase (CYP4F3), indi- 
cating that it is a new member of the CYP4F subfamily. 
Nevertheless, the human liver LTB, w-hydroxylase dif- 
fers from the PMN enzyme in its K, value and tissue 
localization. 
2. Materials and methods 
2.1. Materials 
Restriction enzymes, T4 DNA ligase, and a large fragment of Esch- 
erichia coli DNA polymerase I (KJenow fragment) were purchased from 
Takara Shuzo (Kyoto); llgtl 1 cDNA library of human liver (HLl 115b 
#25596) was from Clontech Laboratories (Palo Alto); [a-‘*P]dCTP (111 
TBq/mmol) was from Radiochemical Center (Amersham). Saccharo- 
myces cerevisiae strain AH22 (a leu2 his4 can1 cir’) was donated by Dr. 
T. Hatano (Fukuyama University), and the yeast expression vector 
pAAH carrying the ADHl promoter and terminator was from Dr. B. 
D. Hall (University of Washington). NADPH-P-450 reductase was 
prepared from rabbit liver microsomes by the method of Taniguchi et 
al. [14]. 
2.2. Cloning procedure 
cDNA clones for human liver LTB4 w-hydroxylase were isolated 
from 4.0 x 10’ recombinant phages with cDNA under high stringency 
conditions using the cDNA for human PMN LTB, w-hydroxylase 
(CYP4F3) [7] as a probe. Plaque hybridization was carried out with the 
3zP-labeled cDNA (specific activity, 2.5 x 10’ cpm/pg) at 65°C in 50 
mM Tris buffer (pH 7.5) containing 1 M NaCI, 10 mM EDTA, 0.1% 
sodium A’-lauroylsarcosinate, 0.2% polyvinylpyrrolidone, 0.2% Ficoll, 
0.2% bovine serum albumin, and 100 ,&nl salmon sperm DNA. The 
filters were washed twice at 65°C for 30 min in 1 x SSC (0.15 M NaCl 
and 0.015 M sodium citrate) and 0.1% N-lauroylsarcosinate. Positive 
clones were subjected to four rounds of plaque purification, and in- 
serted cDNAs were subcloned into pUC18 plasmid vector at the EcoRI 
site. 
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2.3. DNA sequence analysis 
The plasmid-containing cDNA insert of human liver LTB., o-hy- 
droxylase was digested with several restriction enzymes to identify 
fragments convenient for sequence analysis. Restriction fragments were 
inserted into appropriate vectors, Ml3 mp18 and Ml3 mp19, at the 
polylinker site, and then sequenced by the dideoxy method [15]. All 
sequencings were performed in both directions. 
2.4. Northern blot analysis of mRNA from human liver 
Four cDNA fragments including a 1749-bp CYP4F3 cDNA [7] insert 
(specific activity, 2.1 x 10’ cpm/mg) and its 142-bp Zfinff-PvuII restric- 
tion fragment, 236-377 (specific activity, 1.2 x lo8 cpm/mg), and a 2227- 
bp LB3 cDNA insert (specific activity, 2.3 x lo* cpm/mg) and its 106-bp 
PvuII-PvuII fragment, 279-384 (specific activity, 1.5 x 10’ cpm/mg) 
were used as probes (Fig. 1). Poly(A) RNA (1 pg) from the human liver, 
kidney, and PMN were denatured, electrophoresed on a 0.8% agarose 
gel containing 2.2 M foramide, then transferred onto a nitrocellulose 
filter. The filters were hybridized with each “P-labeled probe and 
washed twice at 50°C for 30 min in 0.1 x SSC and 0.2% sodium 
N-lauroylsarcosinate as described [7]. 
2.5. Expression of liver LTB, w-hydroxylase in yeast cells 
Yeast expression vector, pAAH5, and LB3 cDNA were used to 
express liver LTB, w-hydroxylase. Hind111 linkers (CCCAAGCTTA- 
AAAAA) were constructed just before the initiation codon, ATG, and 
at EcoRV restriction site in position 1714 of LB3 cDNA by the poly- 
merase chain reaction. This modified cDNA fragment was digested 
with HindIII, and inserted into expression vector, pAAH at the 
Hind111 site. Its orientation was determined by restriction enzyme map- 
ping. Transfection and cultivation of yeast cells were carried out as 
described [7]. Yeast microsomes were suspended in 0.1 M potassium 
phosphate buffer (pH 7.5) containing 20% glycerol, 1 mM DTT, and 
1 mM EDTA to give a concentration of 20 mg of protein per ml. 
2.6. Activity assay 
LTB, w-hvdroxvlase activity was determined as described 171. The 
reaction‘mixture containing 340 mM sucrose, 20 mM HEPES (pfi 7.5), 
1 mM EDTA. 1 mM DTT. 1 mM NADPH. 70 uM LTB,. and human 
liver microsomes (0.2 mg of protein) or yeast microsome~ (0.1-0.5 mg 
of protein), in a total volume of 0.2 ml, was incubated at 37°C for 10 
min. The reaction product was extracted and determined as described 
[7]. Microsomal activities of fatty acid and prostaglandin (PG) A, 
hydroxylation were determined as described [16]. The concentration of 
P-450 was determined by the method of Omura and Sato [17]. Micro- 
somes from yeast harboring pAAH without the cDNA insert were 
used for control experiments. 
3. Results and discussion 
3.1. LTB, w-hydroxylation by human liver microsomes 
We have examined P-450 contents and LTB4 o-hy- 
droxylase activities of microsomes prepared from the 
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normal portions of 14 human liver specimens resected 
for hepatocellular carcinoma (Table 1). Incubation of the 
individual microsomes with LTB, in the presence of 
NADPH for 10 min resulted in the formation of 
w-hydroxy LTB, (20-OH-LTBJ. No (w-1)-hydroxy 
LTB4 (19-OH-LTB,) was detected. The LTB, o-hydrox- 
ylase activity was strongly inhibited by carbon monox- 
ide, 1 mM SKF 525-A, and 1 mM metyrapone. No activ- 
ity was observed in the absence of NADPH. These 
results suggest he presence of a P-450(s) responsible for 
the o-hydroxylation of LTB, in human liver micro- 
somes. 
3.2. Isolation of cDNA clone for human liver LTB, 
w-hydroxylase 
We observed that the mRNA hybridized to the whole 
CYP4F3 cDNA [7] is expressed in the human liver and 
kidney as well as human PMN (Fig. 1A). In contrast, a 
significant signal was observed only in human PMN, but 
not in human liver and kidney, when the 142-bp HinfI- 
PvuII restriction fragment at position 236-377 of 
CYP4F3 cDNA was used as a probe (Fig. 1B). These 
findings prompted us to isolate a cDNA specific to 
human liver LTB4 w-hydroxylase. Approximately 
4.0 x lo5 plaques from a human liver cDNA library were 
screened with the CYP4F3 cDNA [7] as a probe. Sixteen 
positive plaques were obtained and subjected to four 
rounds of plaque purification. Seven clones of longer 
than 1.5-kbp were sequenced to about 200-bp of both 
ends. One clone, designated LB3, had an initiation 
codon, ATG, in its 5’-end. The other 6 clones carried the 
same, but shorter cDNA insert. LB3 cDNA contained 
an insert of about 2.2-kbp in size. 
Fig. 2 shows the nucleotide and deduced amino acid 
sequences for LB3 cDNA together with those for PMN 
LTB, o-hydroxylase (CYP4F3) for comparison. LB3 
cDNA contained 2,227 nucleotides and lacked the 
poly(A) tail. An open reading frame at position 42-1601 
was followed by a termination codon at position 1602- 
1604 and a 621-bp 3’-untranslated sequence. The open 
reading frame encoded a protein of 520 amino acids with 
a molecular weight of 59,853 Da. An invariant cysteine 
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Fig. 1. Blot analysis of the poly(A) RNA from human liver, kidney, and PMN. mRNA (1 pg) prepared from human liver, kidney, and PMN were 
separated on an 0.8% denaturing agarose gel, transferred to the nitrocellulose filter, and hybridized with four ‘*P-labeled cDNA fragments. 
(A) 1749-bp human PMN LTB, w-hydroxylase (CYP4F3) cDNA insert [A; (B) 142-bp Hint’-PvuII restriction fragment (236377) of CYP4F3 [7]; 
(C) 2227-bp LB3 cDNA insert; @) 106-bp PvuII-PvuII fragment (279-384) of LB3 cDNA insert. Lane 1, liver; lane 2, kidney; lane 3, PMN. 
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Fig. 2. Nucleotide sequences of human liver and PMN LTB, w-hydroxylase cDNAs and their deduced amino acid sequences, The whole nucleotide 
and amino acid sequences of liver LTB, w-hydroxylase cDNA are shown (‘liver’). Only the nucleotides and amino acids of PMN LTB, ru-hydroxylase 
cDNA (CYP4F3) [7] that are not identical with those of the liver enzyme cDNA are presented (‘PMN’). A putative heme-binding cysteine residue 
is underlined. 
residue was found to be located at position 468 in the 
conserved region among all P-450s examined [l&19]. 
The cDNA-deduced amino acid sequence showed 87.3% 
homology with that of CYP4F3 [7]. However, the re- 
gions with low homology between the two P-450s were 
found to be present at position 61-114 of the amino acid 
sequence (29.6%) and at position 223-381 (LB3) of the 
nucleotide sequence (49.7%), although other sequences 
showed high homology (91.5%) with each other. The 
primary structure of the protein encoded by LB3 cDNA 
had 3145% homology with those of members of the 
CYP4A [2&22], CYP4B [23] and CYP4C [24] subfami- 
lies, and showed 78.5% homology with that of CYP4F1, 
the mRNA of which was detected in rat hepatic tumors 
[25]. These results indicate that the P-450 encoded by 
LB3 cDNA is a new member of the CYP4F subfamily. 
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Fig. 3. HPLC of 20-OH-LTB, produced from LTB, by yeast microsomes transfected with LB3 cDNA. Reaction conditions are described in the text. 
(A) Incubation for 5 min; (B) zero time 
Table 1 
Microsomal LTB, w-hydroxylase activity in human liver 
Case Specific content of P-450 Activity (pmol 
(nmol P-45O/mg protein) product/min/mg protein) 
1 0.12 41 
2 0.07 18 
3 0.21 18 
4 0.13 46 
5 0.38 78 
6 0.07 38 
7 0.07 49 
8 0.10 20 
9 0.08 22 
10 0.05 11 
11 0.22 32 
12 0.08 42 
13 0.07 39 
14 0.15 81 
The reaction conditions are given in the text. 
3.3. Expression in yeast 
Microsomal fractions obtained from yeast cells trans- 
fected with the expression vector pAAH carrying re- 
combinant LB3 cDNA showed approximately 0.06 nmol 
of P-45O/mg of protein, whereas no P-450 was detected 
in control yeast cells. The transfected yeast microsomes 
catalyzed the hydroxylation of LTB, solely at the 
o-position with a turnover rate of 2.6 nmol/min/nmol of 
P-450 (Fig. 3). No activity was detected with laurate, 
arachidonate, or PGA,. The apparent Km for LTB, was 
44.8 PM. This value is 63-fold higher than that for PMN 
LTB, w-hydroxylase (CYP4F3)[7j. Addition of rabbit 
liver NADPH-P-450 reductase had little effect. In con- 
trast, no activity was observed in the absence of 
NADPH. These results demonstrate that LB3 cDNA 
encodes human liver LTB, w-hydroxylase. 
3.4. Northern blot analysis 
Northern blot analysis showed that the whole LB3 
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cDNA hybridized strongly with mRNA in human liver 
and PMN, with a weaker hybridization signal being ob- 
served in human kidney (Fig. 1C). However, when the 
cDNA fragment at position 279-384 (P&I-PvuII) of 
LB3 cDNA was used as a probe to minimize cross-hy- 
bridization, a single signal was detected only in human 
liver (Fig. 1D). These results resemble those of Northern 
blot analysis with the whole CYP4F3 cDNA and its 
specific cDNA fragment as probes (Fig. 1A and B). 
These findings indicate that human liver and PMN LTB4 
w-hydroxylases are specifically expressed in the corre- 
sponding tissues. 
In humans, LTB, is metabolized by two different path- 
ways, one of which is w-oxidation in PMN [2-6], the 
other being the 10, 1 I-reductase pathway in various 
human cells such as lung macrophage [26], glomerular 
mesangial cells [27] and keratinocytes [28], and lung tis- 
sue [29]. However, little information is available on the 
metabolism of LTB, in human liver. In this paper, we 
showed that LTB, is hydroxylated at the w-position by 
microsomes from all of the 14 human liver specimens 
examined. Furthermore, we have isolated and sequenced 
the cDNA encoding human liver LTBI w-hydroxylase. 
This enzyme exhibited 87.3% homology with human 
PMN LTB, o-hydroxylase (CYP4F3)[7] in its amino 
acid sequence, indicating that it is a member of the 
CYP4F subfamily. However, the K, of the liver enzyme 
is 63-fold higher than that of the PMN enzyme. These 
two enzyme are separately expressed in the liver and 
PMN. Preliminary studies on the purification indicate 
that the liver enzyme is much more unstable compared 
to the PMN enzyme. The liver is the major site for the 
uptake and degradation of leukotrienes. We suggest hat 
the human liver LTB, o-hydroxylase is of great impor- 
tance for the inactivation of LTB4 in human liver. 
References 
[I] Samuelsson, B. (1983) Science 220, 568-575. 
[2] Hansson, G., Lindgren, J.A., Dahlen, S.E., Hedqvist, P. and 
Samuelsson, B. (1981) FEBS Lett. 130, 107-112. 
[3] Shak, S. and Goldstein, I.M. (1984) J. Biol. Chem. 259, 10181- 
10187. 
[4] Shak, S. and Goldstein, I.M. (1985) J. Clin. Invest. 76, 1218-1228. 
[5] Sobennan, R.J., Okita, R.T., Fitzsimmons, G., Rokach, J., Spur, 
B. and Austen, K.F. (1987) J. Biol. Chem. 262, 12421-12427. 
[6] Sumimoto, H., Takeshige, K. and Minakami, S. (1988) Eur. J. 
Biochem. 172, 315-324. 
[7] Kikuta, Y., Kusunose, E., Endo, K., Yamamoto, S., Sogawa, K., 
Fujii-Kuriyama, Y. and Kusunose, M. (1993) J. Biol. Chem. 268, 
93769380. 
[8] Kusunose, M. (1993) in: Cytochrome P-450,2nd edition (Omura, 
T., Ishimura, Y. and Fujii-Kuriyama, Y., eds.) pp. 127-141, 
Kodansha, Tokyo. 
[9] Nelson, D.E., Kamataki, T., Waxman, D.J., Guengerich, P., Es- 
tabrook, R.W., Feyereisen, R., Gonzalez, F.J., Coon, M.J., Gun- 
salus, I.C., Gotoh, O., Okuda, K. and Nebert, D.W. (1993) DNA 
Cell Biol. 12, 1-51. 
[lo] Romano, M.C., Eckardt, R.D., Bender, P.E., Leonard, T.B., 
Straub, K.M. and Newton, J.F. (1987) J. Biol. Chem. 262, 1590- 
1595. 
[ll] Sumimoto, H., Kusunose, E., Gotoh, Y., Kusunose, M. and 
Minakami, S. (1990) J. Biochem. 108, 215-221. 
[12] Baumert, T., Huber, M., Mayer, D. and Keppler, D. (1989) Eur. 
J. Biochem. 182, 223-229. 
[13] Huwyler, J., Jedlitschky, G., Keppler, D. and Gut, J. (1992) Eur. 
J. Biochem. 206, 869-879. 
[14] Taniguchi, H., Imai, Y., Iyanagi, T. and Sato, R. (1979) Biochim. 
Biophys. Acta 550, 341-356. 
[15] Sanger, R., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. 
Acad. Sci. USA 74, 5463-5467. 
1161 Sawamura, A., Kusunose, E., Satouchi, K. and Kusunose, M. 
(1993) Biochim. Biophys. Acta 1168, 30-36. 
[17] Omura, T. and Sato, R. (1964) J. Biol. Chem. 239, 2379-2385. 
[18] Gotoh, O., Tagashira, Y., Iizuka, T. and Fujii-Kuriyama, Y. 
(1983) J. Biochem. 93, 807-817. 
[19] Makino, R. and Shimada, H. (1993) in: Cytochrome P-450, 2nd 
edition (Omura,T., Ishimura, Y. and Fujii-Kuriyama, Y., eds.) pp. 
17-30, Kodansha, Tokyo. 
[20] Hardwick, J.P., Song, B.-J., Huberman, E. and Gonzalez, F.J. 
(1987) J. Biol. Chem. 262, 801-810. 
[21] Matsubara, S., Yamamoto, S., Sogawa, K., Yokotani, N., Fujii- 
Kuriyama, Y., Haniu, M., Shively. J.E.? Gotoh, O., Kusunose, E. 
and Kusunose, M. (1987) J. Biol. Chem. 262, 1336613371. 
[22] Yokotani, N., Bernhardt, R., Sogawa, K., Kusunose, E., Gotoh, 
O., Kusunose, M. and Fujii-Kuriyama, Y. (1989) J. Biol. Chem. 
264, 21665-21669. 
[23] Yokotani, N., Sogawa, K., Matsubara, S., Gotoh, O., Kusunose, 
E., Kusunose, M. and Fujii-Kuriyama, Y. (1990) Eur. J. Biochem. 
187, 23329. 
[24] Bradfield, J.Y., Lee, H.-U. and Keeley, L.L. (1991) Proc. Natl. 
Acad. Sci. USA 88, 807-8117. 
[25] Chen, L. and Hardwick, J.P. (1993) Arch. Biochem. Biophys. 300, 
18-23. 
[26] Schonfeld, W., Schluter, B., Hilger, R. and Koning, W. (1988) 
Immunology 65, 529-536. 
[27] Kaever, V., Bruuns, J., Wunder, J., Damerau, B., Zimmer, G., 
Fauler, J., Wessel, K., Floege, J., Topley, N., Radeke, H. and 
Resch, K. (1990) Life Sci. 46, 1465-1470. 
[28] Wheelan, P., Zirrolli, J.A., Morelli, J.C. and Murphy, R.C. (1993) 
J. Biol. Chem. 268, 25439-25448. 
[29] Kumlin, M., Falck, J.R., Raud, J., Harada, Y., Dahlen, S.-E. and 
Granstrom, E. (1990) Biochem. Biophys. Res. Commun. 170,23- 
29. 
